Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 496 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% normal saline injection Clear all
Recruiting Phase 4 Interventional

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

NCT07220382
View directory record Official record
Conditions
Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions
OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 9, 2026, 11:57 PM EDT
Recruiting Phase 2 Interventional

Tocilizumab in Lung Transplantation

NCT06033196
View directory record Official record
Conditions
Lung Transplant
Interventions
Tocilizumab, Placebo for Tocilizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

NCT01143246
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Terlipressin, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures

NCT02967172
View directory record Official record
Conditions
Pain, Postoperative, Ankle Fractures
Interventions
Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 9, 2026, 11:57 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section

NCT03383588
View directory record Official record
Conditions
Pain, Referred
Interventions
Bupivacaine, Morphine, Fentanyl, Epinephrine, Saline solution
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
17 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Percutaneous Lumbar Epidural Adhesiolysis and Neurolysis on Low Back Pain

NCT00370994
View directory record Official record
Conditions
Low Back Pain
Interventions
Caudal epidural injection, Percutaneous adhesiolysis
Procedure
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 9, 2026, 11:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers of Trained Immunity Following MMR Vaccination

NCT04646239
View directory record Official record
Conditions
Covid19
Interventions
Heterologous stimuli, Neutralization assay
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 2 Interventional

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

NCT05717062
View directory record Official record
Conditions
Snakebite, Envenoming, Snake
Interventions
Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 9, 2026, 11:57 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, GLSI-100
Biological
Lead sponsor
Greenwich LifeSciences, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
51
States / cities
Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 9, 2026, 11:57 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

NCT05805826
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
936 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
23
States / cities
Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

Triptorelin for Ovary Protection in Childhood Onset Lupus

NCT00124514
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Triptorelin Pamoate, placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
9 Years to 21 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 9, 2026, 11:57 PM EDT
Terminated Phase 2 Interventional Results available

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT01727336
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma
Interventions
Dalantercept and axitinib, Placebo and axitinib
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
36
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

Imaging in MGUS, SMM and MM

NCT01237054
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
18-NaF PET, DCE-MRI, 18-FDG PET/CT
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 2 Interventional

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

NCT05953480
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Redasemtide, Placebo
Biological · Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
17
States / cities
Tucson, Arizona • Sarasota, Florida • Augusta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

NCT04670614
View directory record Official record
Conditions
Post-operative Surgical Pain
Interventions
Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Study of Postoperative Analgesia in Bunionectomy

NCT00890682
View directory record Official record
Conditions
Bunion, Hallux Valgus
Interventions
SKY0402, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease

NCT03301272
View directory record Official record
Conditions
Parkinson Disease
Interventions
Onabotulinumtoxin A Injection, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 9, 2026, 11:57 PM EDT
Active, not recruiting Phase 1 Interventional

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

NCT05743881
View directory record Official record
Conditions
Respiratory Syncytial Virus, Human Metapneumovirus
Interventions
mRNA-1345, mRNA-1365, Placebo, Nimenrix
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
5 Months to 24 Months
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

NCT02860650
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Filo, MVA-BN-Filo, Ad26.ZEBOV, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 4 Interventional

Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries

NCT02980835
View directory record Official record
Conditions
Video-Assisted Thoracic Surgery, Video-Assisted Thoracoscopic Surgery
Interventions
Normal Saline, Ropivacaine, Epinephrine, Dexamethasone
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

EXPAREL for Minimally Invasive Supracervical Hysterectomies

NCT03769714
View directory record Official record
Conditions
Pain
Interventions
Saline Solution for Injection, Exparel
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 9, 2026, 11:57 PM EDT
Completed Phase 4 Interventional Results available

Oral Versus Intravenous Sedation for Ocular Procedures

NCT03246724
View directory record Official record
Conditions
Surgery, Sedation
Interventions
Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 9, 2026, 11:57 PM EDT